CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials. One trial will assess treatment differences between intensive medical management alone compared to CEA plus intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to CAS plus intensive medical management. Intensive medical management will involve control of blood pressure, LDL cholesterol, cigarette smoking, and other vascular risk factors.
|Effective start/end date||3/15/14 → 2/29/20|
- Mayo Clinic-Jacksonville (SP0031679//U01NS080168-01A1)
- National Institute of Neurological Disorders and Stroke (SP0031679//U01NS080168-01A1)